OncoDNA and its partners are proud to be Selected by the oncNGS Consortium to Develop a Solution for the Liquid Biopsies
JOINT PARTICIPATION TO DEVELOP A SOLUTION FOR ANALYSIS IN LIQUID BIOPSIES OF SOLID TUMORS BASED ON NGS TECHNOLOGY
OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, has announced its participation in the oncNGS tender. Together with IQVIA, we are challenged by the oncNGS consortium to come up with a solution for analysis in liquid biopsies which should represent the ‘best NGS test, for all solid and lymphoid tumors’.
The oncNGS consortium composed of eight health procurers from Belgium, France, Germany, Spain and Italy, challenges the market to carry out research on integrated solutions that can radically change cancer patients' experience by means of predictive diagnosis, prognosis and theragnosis capabilities based on Next Generation Sequencing (NGS) technology.
The consortium asks the market to perform research and development on an NGS tumor-marker liquid biopsy kit that will include clinical workflow, wetlab analysis, bioinformatics analysis (drylab), molecular & clinical interpretation and reporting. This solution should be applicable to all tumor types.
“There is a need for a minimally invasive, scalable, and cost-efficient solutions in Europe for screening and diagnosing cancer. oncNGS pre-commercial procurement project was set up to achieve this and we received many proposals from both leading academic institutions and private companies to deliver the solution according to our requirements. Four novels approaches have been selected to start with the research and design of the solutions in the Phase 1. We are looking forward to start collaborating with them.” –mentioned OncNGS buyers group.
Marc Van Den Bulcke, head of the Cancer Centre, Sciensano, member of the oncNGS buyer group and lead procurer said: “We are very excited to start this trajectory with the four suppliers.”
With its many years of experience in testing and interpreting oncological samples, OncoDNA is convinced that a solution can be developed to meet the consortium level of expectations. “We are very happy to be supported by IQVIA who brings a wealth of expertise in hospitals’ data management, combined with extensive knowledge in real world evidence gathering and making an economical viable model into the healthcare system”.
OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – Biosequence and IntegraGen – are based in Spain, France and the United States. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
For further information, visit www.oncodna.com and connect with us on LinkedIn, Facebook or Twitter.
KOENRAAD EYCKEN, Chief Product Officer, OncoDNA (+32 488 07 48 01)